Boehringer Ingelheim acquires GST to expand stem cell capabilities

By Nikita Chaurasia  Date: 2020-07-29

Boehringer Ingelheim acquires GST to expand stem cell capabilities

Boehringer Ingelheim, a leader in pharmaceutical products, has recently made it to the headlines by acquiring Belgium-based veterinary biotech firm, Global Stem cell Technology (GST).

According to reliable sources, the collaboration with GST will allow Boehringer to expand its development pipeline, while parallelly focusing on setting higher standards of animal healthcare. However, the financial details of the deal were not disclosed.

The two companies had initially partnered in the year 2018 and had launched a stem cell product, Arti-Cell® Forte in 2019.  Arti-Cell® Forte is apparently the first stem cell product which was granted marketing authorization by the European commission in the veterinary domain.

Boehringer Ingelheim Animal Health’s Head of Global Strategic Marketing Jean-Luc Michel, was reported stating that the company had finally decided to acquire GST after two years of partnership which will help in expanding Boehringer Ingelheim’s portfolio. He added that GST’s expertise in stem cell production will allow Boehringer to  deliver advanced and innovative solutions to their clients.

Jan Spaas CEO of GST mentioned that that Boehringer Ingelheim’s mission to lead a new wave of development and innovation in the veterinary industry complies with GST vision. He further claimed that GST will operate as a new research and development division Boehringer’s banner.

For those uninitiated, Boehringer Ingelheim Animal Health is one of the largest animal health businesses in the world, with net sales of 4 billion euros in 2019 and presence in more than 150 countries.

On the other hand, Global Stem cell Technology (GST) is a biotech company with primary focus on R&D activities and manufacture of veterinary stem cell-based products.

In other news, Boehringer Ingelheim had recently teamed up with Biognosys to enhance next-gen proteomics applications for drug development and discovery.

Source credits: https://www.boehringer-ingelheim.com/press-release/boehringer-ingelheim-acquires-global-stem-cell-technology

https://www.news-medical.net/news/20200724/Boehringer-Ingelheim-and-Biognosys-join-forces-on-applying-quantitative-proteomics-tools-in-drug-discovery.aspx

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

India’s Gennova Biopharmaceutical working on Omicron-specific vaccine

India’s Gennova Biopharmaceutical working on Omicron-specific vaccine

By Nikita Chaurasia

Gennova's potential mRNA vaccine is currently undergoing Phase II and Phase III trials. If approved for a EUA, it would be India’s first mRNA COVID-19 vaccine. Gennova Biopharmaceutical, a subsidiary of Pune-based drugmaker Emcure, is...

Recykal secures USD 22 Mn in a fundraise led by Morgan Stanley India

Recykal secures USD 22 Mn in a fundraise led by Morgan Stanley India

By Nikita Chaurasia

Recykal, a B2B waste management and recycling marketplace head-quartered in Hyderabad, has reportedly raised USD 22 million in funding from Morgan Stanley India. According to the company, existing investors including Circulate Capital, Arun Venkatac...

Reliance buys controlling stake in NYC hotel in its hospitality push

Reliance buys controlling stake in NYC hotel in its hospitality push

By Nikita Chaurasia

Reliance Industries Ltd. is reportedly planning to acquire a controlling stake in New York's five-star Mandarin Oriental Hotel for around USD 100 million. The company stated in a stock exchange filing that its industrial investments subsidiary, ...

India inoculates 3.8 million teens over fears of third COVID-19 wave

India inoculates 3.8 million teens over fears of third COVID-19 wave

By Nikita Chaurasia

India has reportedly vaccinated over 3.8 million teens aged between 15-18 years as of 3rd January in an effort to boost its inoculation drive to protect the large young population before the onslaught of a possible third wave of coronavirus infection...

Apple on track to become the world’s first USD 3 trillion company

Apple on track to become the world’s first USD 3 trillion company

By Nikita Chaurasia

Tech giant Apple Inc. has once again become the world’s most valuable company as it is just a hair's breadth away from a market capitalization of USD 3 trillion. On Monday, the iPhone maker’s shares slid a little over 2% to USD 175.7...